Drug Safety

, Volume 28, Issue 3, pp 241–249 | Cite as

Tibolone and Endometrial Cancer

A Cohort and Nested Case-Control Study in the UK
  • Corinne S. de Vries
  • Susan E. Bromley
  • Hilary Thomas
  • Richard D.T. Farmer
Original Research Article

Abstract

Objective: Case series and spontaneous reports of endometrial cancer have raised the question as to whether the use of tibolone (introduced into the UK in 1991) is associated with an increased risk of endometrial cancer. This study set out to evaluate whether tibolone use is associated with an increased risk of endometrial cancer.

Methods: Age-adjusted incidence rate ratios (IRRs) of endometrial cancer were calculated for tibolone use compared with the use of other hormone replacement therapy (HRT). Separate sets of controls, matched for age and general practice, were compared with cases, all nested within a cohort of HRT users identified from the UK General Practice Research Database (GPRD). Conditional logistic regression analysis, adjusted for potential confounders, was used to study the association between tibolone use and the risk of endometrial cancer.

Results: 4995 women used tibolone as their first HRT product; 10 783 (4.3%) of the users of combined HRT had changed to tibolone at some time during the study period. Amongst women whose HRT began with tibolone, the age-adjusted IRR relative to those who started with combined sequential HRT was 1.83 (95% CI 1.19, 2.82). The nested case-control study comprised 162 cases, each matched to two sets of 972 controls. There were 43 tibolone-exposed subjects, 28 of whom had used other HRT before or after tibolone. The adjusted odds ratio of the risk of endometrial cancer in women who had ever used tibolone, compared with users of combined sequential HRT, was 1.54 (95% CI 1.03, 2.32) in the age-matched set and 1.58 (95% CI 1.01, 2.47) in the practice-matched set. Sensitivity analyses did not decrease the risk estimates found.

Discussion: Tibolone may be associated with an increased risk of endometrial cancer compared with conventional forms of HRT, but our data are fragile. Residual bias and uncontrolled confounding cannot be excluded, and follow-up time is insufficient to draw any firm conclusions with respect to the endometrial safety of tibolone.

Notes

Acknowledgements

We are indebted to the members of the independent scientific advisory board for overseeing this study. They advised on methodological issues, provided essential background information, advised on interpretation of the results and commented on a draft of this manuscript. Dr Tim Williams extracted controls for the study from the GPRD and carried out part of the mapping of HRT products in an attempt to establish duration of use. The study was funded through an unconditional research grant from Organon NV, The Netherlands.

The study was overseen by an independent scientific advisory board comprising experts in gynaecological oncology, pathology, (pharmaco)epidemiology and statistics and the study was carried out in accordance with their recommendations. The funding organisation was not present at the meetings of the scientific advisory board and had no say in the way in which the study was carried out. The research contract was unconditional and the authors have the right to publish without consulting the funding organisation.

References

  1. 1.
    Von Dadelszen P, Gillmer MDG, Gray MD, et al. Endometrial hyperplasia and adenocarcinoma during tibolone (Livial®) therapy. Br J Obstet Gynaecol 1994; 101: 158–61CrossRefGoogle Scholar
  2. 2.
    Office for National Statistics. Cancer registration statistics. England, 1992-2001 [online]. Available from URL: http://www.statistics.gov.uk/statbase/Product.asp?vlnk=8843 [Accessed 2004 Sep 30]Google Scholar
  3. 3.
    Parsons AK, Londono JL. Detection and surveillance of endometrial hyperplasia and carcinoma. In: Lobo RA, editor. Treatment of the postmenopausal woman: basic and clinical aspects. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1999Google Scholar
  4. 4.
    Herbst AL. Neoplastic diseases of the uterus. In: Mishell DR, Stenchever MA, Droegemueller W, et al., editors. Comprehensive gynecology. 3rd ed. St Louis (MO): Mosby-Year Book Inc., 1997Google Scholar
  5. 5.
    Collins JA, Schlesselman JJ. Hormone replacement therapy and endometrial cancer. In: Lobo RA, editor. Treatment of the postmenopausal woman: basic and clinical aspects. 2nd ed. Philadelphia (PA): Lippincott Williams & Wilkins, 1999Google Scholar
  6. 6.
    Bergman L, Beelen MLR, Gallee MPW, et al. Comprehensive Cancer Centres’ ALERT Group: risk and prognosis of endometrial cancer after tamoxifen for breast cancer. Lancet 2000; 356: 881–7PubMedCrossRefGoogle Scholar
  7. 7.
    The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: the postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996; 275: 370–5Google Scholar
  8. 8.
    Tang B, Markiewicz L, Kloosterboer HJ, et al. Human endometrial 3β-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestogenic activity ratios of steroidal drugs. J Steroid Biochem Mol Biol 1993; 45: 345–51PubMedCrossRefGoogle Scholar
  9. 9.
    Rymer JM. The effects of tibolone. Gynecol Endocrinol 1998; 12: 213–20PubMedCrossRefGoogle Scholar
  10. 10.
    Bromley SE, de Vries CS, Farmer RDT. Utilisation of hormone replacement therapy in the United Kingdom: a descriptive study using the General Practice Research Database. Br J Obstet Gynaecol 2004; 111(4): 369–76CrossRefGoogle Scholar
  11. 11.
    Rymer J, Fogelman I, Chapman MG. The incidence of vaginal bleeding with tibolone treatment. Br J Obstet Gynaecol 1994; 101: 53–6PubMedCrossRefGoogle Scholar
  12. 12.
    Genazzani AR, Benedek-Jaszmann LJ, Hart DM, et al. Org OD 14 and the endometrium. Maturitas 1991; 13: 243–51PubMedCrossRefGoogle Scholar
  13. 13.
    Meuwissen JHJM, Wiegerinck MAHM, Haverkorn MJ. Regression of endometrial thickness in combination with reduced withdrawal bleeding as a progestational effect of tibolone in postmenopausal women on oestrogen replacement therapy. Maturitas 1995; 21: 121–5PubMedCrossRefGoogle Scholar
  14. 14.
    García Rodriguez LA, Perez-Gutthann S, Jick S. The UK General Practice Research Database. In: Strom BL, editor. Pharmacoepidemiology. 3rd ed. Chichester: John Wiley & Sons Ltd, 2000Google Scholar
  15. 15.
    Hollowell J. The General Practice Research Database: quality of morbidity data. Popul Trends 1997; 87: 36–40PubMedGoogle Scholar
  16. 16.
    Walley T, Mangani A. The UK General Practice Research Database. Lancet 1997; 350: 1097–9PubMedCrossRefGoogle Scholar
  17. 17.
    StataCorp. Stata Statistical Software: Release 8.0. College Station (TX): StataCorp LP, 2001Google Scholar
  18. 18.
    Hill DA, Weiss NS, Beresford SAA, et al. Continuous combined hormone replacement therapy and risk of endometrial cancer. Am J Obstet Gynecol 2000; 183: 1456–61PubMedCrossRefGoogle Scholar
  19. 19.
    Grady D, Gebretsadik T, Kerlikowske K, et al. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. Obstet Gynecol 1995; 85: 304–13PubMedCrossRefGoogle Scholar
  20. 20.
    Beresford SAA, Weiss NS, Voigt LF, et al. Risk of endometrial cancer in relation to use of oestrogen combined with cyclic progestagen therapy in postmenopausal women. Lancet 1997; 349: 458–61PubMedCrossRefGoogle Scholar
  21. 21.
    Weiderpass E, Adami HO, Baron JA, et al. Risk of endometrial cancer following estrogen replacement with and without progestins. J Natl Cancer Inst 1999; 91: 1131–7PubMedCrossRefGoogle Scholar
  22. 22.
    De Vries CS, Bromley SE, Williams TJ, et al. Risk factors associated with endometrial cancer [abstract]. Pharmacoepidemiol Drug Saf 2001; 10: S84Google Scholar
  23. 23.
    Burger CW, Van Unnik GA, Kenemans P. Hormone replacement therapy and endometrial cancer. In: Genazzani AR, editor. Hormone replacement therapy and cancer: the current status of research and practice. London: The Parthenon Publishing Group, 2002Google Scholar
  24. 24.
    Davies AP, Oram D. Exacerbation of adenomyosis in a postmenopausal woman taking tibolone associated with an elevation in serum CA 125. Br J Obstet Gynaecol 1994; 101: 632–3PubMedCrossRefGoogle Scholar
  25. 25.
    Dören M, Rübig A, Coelingh Bennink FJT, et al. Impact on uterine bleeding and endometrial thickness: tibolone compared with continuous combined estradiol and norethisterone acetate replacement therapy. Menopause 1999; 6: 299–306PubMedCrossRefGoogle Scholar
  26. 26.
    Wiegratz I, Sanger N, Kuhl H. Formation of 7-alpha-ethinyl estradiol during treatment with tibolone. Menopause 2002; 9: 293–5PubMedCrossRefGoogle Scholar
  27. 27.
    Bodine PV, Harris HA, Lyttle CR, et al. Estrogenic effects of 7-alpha-methyl-17-alpha ethynynlestradiol: a newly discovered tibolone metabolite. Steroids 2002; 67: 681–6PubMedCrossRefGoogle Scholar

Copyright information

© Adis Data Information BV 2005

Authors and Affiliations

  • Corinne S. de Vries
    • 1
  • Susan E. Bromley
    • 1
  • Hilary Thomas
    • 2
  • Richard D.T. Farmer
    • 1
  1. 1.Department of Pharmacoepidemiology, Postgraduate Medical SchoolUniversity of SurreyGuildfordUK
  2. 2.Department of Oncology, Postgraduate Medical SchoolUniversity of SurreyGuildfordUK

Personalised recommendations